Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up-Reference-Cited by-同舟云学术

Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up

Published:2015-08-31 Issue:1 Volume:55 Page:143-148
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:Rheumatology

Author:

Chen Der-Yuan,Chen Yi-Ming,Hsieh Tsu-Yi,Hung Wei-Ting,Hsieh Chia-Wei,Chen Hsin-Hua,Tang Kuo-Tung,Lan Joung-Liang

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/55/1/143/18096668/kev298.pdf

Reference20 articles.

1. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register

2. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects

3. A multicenter, randomized, controlled open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients in stable clinical remission;Chatzidionysiou;Arthritis Rheum,2012

4. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

5. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial;Rheumatology International;2024-07-24

2. What are the benefits of therapeutic drug monitoring in the optimization of adalimumab therapy? a systematic review and meta-analysis up to 2022;Frontiers in Pharmacology;2024-07-08

3. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide;Reumatología Clínica;2024-07

4. Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases;Pediatric Rheumatology;2024-01-02

5. Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn’s disease;Therapeutic Advances in Gastroenterology;2024-01